Collectively, the PNPLA3 I148M variant represents not only a major genetic driver of MASLD and its complications but also a potential biomarker for fibrosis and HCC risk, as well as a promising target for precision therapeutics (111, 112)
The agency must still complete its review and decide whether and how to act
Coverage Considerations Saxenda: Longer FDA approval history (2014) may mean better coverage on some plans Step therapy: Some plans require trying Saxenda before approving Zepbound Zepbound: Superior efficacy (20.9% vs ~8% weight loss) may justify coverage even if more expensive Cash Pay Options If insurance doesn't cover your preferred option: Zepbound via LillyDirect: $299$449/month (vials, Dec 2025) Saxenda: ~$1,400/month retail
It is the first line of defense against our cells' most violent attackers, namely free radicals, chemical toxins, radiation and heavy metals
The lowest effective dose in males (0.01 mg/kg) failed to significantly reduce alcohol-appropriate responding in females, suggesting lower sensitivity in females
All antipsychotic medication doses were converted to chlorpromazine equivalents [29]